

Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-Apr-2021  
Document Type: USP Monographs  
DocId: GUID-4F3293AD-AF3C-4295-A7CB-FA38D3505CB8\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M5587\\_03\\_01](https://doi.org/10.31003/USPNF_M5587_03_01)  
DOI Ref: 6j fz7

© 2025 USPC  
Do not distribute

# Diclofenac Sodium Topical Solution

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click <https://www.uspnf.com/rb/diclofenac-na-topical-solution-20210326>.

## DEFINITION

Diclofenac Sodium Topical Solution is a solution of Diclofenac Sodium in a suitable vehicle. It contains NLT 90.0% and NMT 110.0% of the labeled amount of diclofenac sodium ( $C_{14}H_{10}Cl_2NNaO_2$ ).

## IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

## ASSAY

### PROCEDURE

**Solution A:** [Phosphoric acid](#) and [water](#) (0.62:1000)  
**Solution B:** 1.86 g of [monobasic sodium phosphate dihydrate](#) in 1000 mL of [water](#)  
**Solution C:** *Solution A* and *Solution B* (50:50)  
**Mobile phase:** [Methanol](#) and *Solution C* (70:30)  
**Diluent:** [Methanol](#) and water (70:30)  
**Standard stock solution:** 0.6 mg/mL of [USP Diclofenac Sodium RS](#) prepared as follows. Transfer a quantity of [USP Diclofenac Sodium RS](#) to a suitable volumetric flask, add 20% of the flask volume of [methanol](#), sonicate to dissolve, and dilute with *Diluent* to volume.  
**Standard solution:** 0.06 mg/mL of [USP Diclofenac Sodium RS](#) from *Standard stock solution* diluted with *Diluent*  
**Sample solution:** Nominally 0.06 mg/mL of diclofenac sodium prepared as follows. Transfer a quantity of Topical Solution to a suitable volumetric flask, add 20% of the flask volume of [methanol](#), sonicate for about 10 min, and dilute with *Diluent* to volume. Pass a portion of the solution through a suitable filter of 0.45-µm pore size.

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC  
**Detector:** UV 254 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.  
**Column:** 4.6-mm × 25-cm; 5-µm packing [L7](#)  
**Column temperature:** 30°  
**Flow rate:** 1 mL/min  
**Injection volume:** 10 µL  
**Run time:** NLT 2 times the retention time of diclofenac

### System suitability

**Sample:** *Standard solution*  
**Suitability requirements**  
**Tailing factor:** NMT 2.0  
**Relative standard deviation:** NMT 2.0%

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of diclofenac sodium ( $C_{14}H_{10}Cl_2NNaO_2$ ) in the portion of Topical Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of diclofenac from the *Sample solution*  
 $r_S$  = peak response of diclofenac from the *Standard solution*  
 $C_S$  = concentration of [USP Diclofenac Sodium RS](#) in the *Standard solution* (mg/mL)  
 $C_U$  = nominal concentration of diclofenac sodium in the *Sample solution* (mg/mL)

## IMPURITIES

### • ORGANIC IMPURITIES

**Solution A, Solution B, Solution C, and Diluent:** Prepare as directed in the Assay.

**Mobile phase A:** Use *Solution C*.

**Mobile phase B:** [Methanol](#) and [acetonitrile](#) (90:10)

**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Mobile Phase A (%)	Mobile Phase B (%)
0	40	60
30	40	60
48	25	75
60	25	75
62	40	60
70	40	60

**Standard stock solution:** 0.3 mg/mL of [USP Diclofenac Sodium RS](#) prepared as follows. Transfer a quantity of [USP Diclofenac Sodium RS](#) to a suitable volumetric flask, add 20% of the flask volume of [methanol](#), sonicate to dissolve, and dilute with *Diluent* to volume.

**Standard solution:** 0.003 mg/mL of [USP Diclofenac Sodium RS](#) from *Standard stock solution* diluted with *Diluent*

**Sensitivity solution:** 0.3 µg/mL of [USP Diclofenac Sodium RS](#) in *Diluent* from *Standard solution*

**Sample solution:** Nominally 0.6 mg/mL of diclofenac sodium prepared as follows. Transfer a suitable quantity of the Topical Solution to a suitable volumetric flask, add 20% of the flask volume of [methanol](#), and sonicate to disperse. Add 50% of the flask volume of *Diluent*, sonicate for about 15 min, and dilute with *Diluent* to volume. Pass a portion of the solution through a suitable filter of 0.45-µm pore size.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; 5-µm packing [L1](#)

**Column temperature:** 45°

**Flow rate:** 1.2 mL/min

**Injection volume:** 20 µL

### System suitability

**Samples:** *Standard solution* and *Sensitivity solution*

#### Suitability requirements

**Relative standard deviation:** NMT 5.0%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each specified and any unspecified degradation product in the portion of Topical Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

$r_U$  = peak response of each specified or unspecified degradation product from the *Sample solution*

$r_S$  = peak response of diclofenac from the *Standard solution*

$C_S$  = concentration of [USP Diclofenac Sodium RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of diclofenac sodium in the *Sample solution* (mg/mL)

$F$  = relative response factor (see [Table 2](#))

**Acceptance criteria:** See [Table 2](#).

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Diclofenac keto analog <sup>a</sup>	0.3	1.7	0.2
Diclofenac lactam (diclofenac related compound A) <sup>b</sup>	0.5	1.4	0.5
Diclofenac	1.0	—	—
Unidentified degradation product A	2.2	1.3	0.2
Any unspecified degradation product	—	1.0	0.2
Total degradation products	—	—	1.0

<sup>a</sup> 2-[(2,6-Dichlorophenyl)amino]phenyl-2-oxoacetic acid.

<sup>b</sup> 1-(2,6-Dichlorophenyl)indolin-2-one.

#### SPECIFIC TESTS

• **MICROBIAL ENUMERATION TESTS (61)** and **TESTS FOR SPECIFIED MICROORGANISMS (62)**: The total aerobic microbial count is NMT 10<sup>2</sup> cfu/mL, and the total combined yeasts and molds count is NMT 10 cfu/mL. It meets the requirements of the tests for absence of *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

**Delete the following:**

▲ **pH (791)**: 8.0–10.0 ▲ (RB 1-Apr-2021)

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE**: Store at controlled room temperature.
- **USP REFERENCE STANDARDS (11)**.  
[USP Diclofenac Sodium RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DICLOFENAC SODIUM TOPICAL SOLUTION	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(1)

**Current DocID:** GUID-4F3293AD-AF3C-4295-A7CB-FA38D3505CB8\_3\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M5587\\_03\\_01](https://doi.org/10.31003/USPNF_M5587_03_01)

**DOI ref:** [6j fz7](#)